Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
This article was originally published in The Tan Sheet
Executive Summary
Sales for Wyeth's Alavert (loratadine) totaled $81.6 mil. in 2003, its first full year on the market, following a significant drop in the fourth quarter
You may also be interested in...
Wyeth Foreign Growth Strong While Alavert Sales Pick Up At Home
Sales for Wyeth's non-sedating antihistamine Alavert (loratadine) more than quadrupled compared to the previous quarter
Wyeth Foreign Growth Strong While Alavert Sales Pick Up At Home
Sales for Wyeth's non-sedating antihistamine Alavert (loratadine) more than quadrupled compared to the previous quarter
Wyeth Foreign Growth Strong While Alavert Sales Pick Up At Home
Sales for Wyeth's non-sedating antihistamine Alavert (loratadine) more than quadrupled compared to the previous quarter